These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6767978)

  • 1. The cost effectiveness of therapeutic and prophylactic leukocyte transfusion.
    Rosenshein MS; Farewell VT; Price TH; Larson EB; Dale DC
    N Engl J Med; 1980 May; 302(19):1058-62. PubMed ID: 6767978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of therapeutic and prophylactic leukocyte transfusion.
    Glassman AB
    N Engl J Med; 1980 Sep; 303(13):759-60. PubMed ID: 6772954
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost effectiveness of therapeutic and prophylactic leukocyte transfusion.
    Clift RA; Buckner CD
    N Engl J Med; 1980 Sep; 303(13):760. PubMed ID: 6772955
    [No Abstract]   [Full Text] [Related]  

  • 4. Leukocyte-reduced blood components: patient benefits and practical applications.
    Higgins VL
    Oncol Nurs Forum; 1996 May; 23(4):659-67. PubMed ID: 8735324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality risks, costs, and decision making in transfusion medicine.
    Blumberg N; Heal JM
    Am J Clin Pathol; 2000 Dec; 114(6):934-7. PubMed ID: 11338483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expensive blood safety initiatives may offer less benefit than we think.
    Kamper-Jørgensen M; Hjalgrim H; Edgren G; Titlestad K; Ullum H; Shanwell A; Reilly M; Melbye M; Nyrén O; Rostgaard K
    Transfusion; 2010 Jan; 50(1):240-2. PubMed ID: 19761551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocyte reduction of cellular blood components. Effectiveness, benefits, quality control, and costs.
    Lane TA
    Arch Pathol Lab Med; 1994 Apr; 118(4):392-404. PubMed ID: 8166589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost effectiveness of preoperative autologous blood donations.
    Etchason J; Petz L; Keeler E; Calhoun L; Kleinman S; Snider C; Fink A; Brook R
    N Engl J Med; 1995 Mar; 332(11):719-24. PubMed ID: 7854380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of allogeneic and autologous blood transfusion in Canada. Canadian Cost of Transfusion Study Group.
    Tretiak R; Laupacis A; Rivière M; McKerracher K; Souêtre E
    CMAJ; 1996 May; 154(10):1501-8. PubMed ID: 8625000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia.
    Welch HG; Larson EB
    N Engl J Med; 1989 Sep; 321(12):807-12. PubMed ID: 2505077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicaid-based child restraint system disbursement and education and the vaccines for children program: comparative cost-effectiveness.
    Goldstein JA; Winston FK; Kallan MJ; Branas CC; Schwartz JS
    Ambul Pediatr; 2008; 8(1):58-65. PubMed ID: 18191783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of therapeutic hypothermia after cardiac arrest.
    Merchant RM; Becker LB; Abella BS; Asch DA; Groeneveld PW
    Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):421-8. PubMed ID: 20031872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia.
    Weeks JC; Tierney MR; Weinstein MC
    N Engl J Med; 1991 Jul; 325(2):81-6. PubMed ID: 1904989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative use of recombinant human erythropoietin in pediatric orthopedics: a decision model for long-term outcomes.
    Vitale MG; Roye BD; Ruchelsman DE; Roye DP
    Spine J; 2007; 7(3):292-300. PubMed ID: 17482112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. Gruppo Italiano Trapianto di Midollo Osseo.
    Messori A; Bosi A; Bacci S; Laszlo D; Trippoli S; Locatelli F; Van Lint MT; Di Bartolomeo P; Amici A
    Bone Marrow Transplant; 1999 Mar; 23(5):489-95. PubMed ID: 10100564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
    Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who should be screened for HIV infection? A cost-effectiveness analysis.
    McCarthy BD; Wong JB; Muñoz A; Sonnenberg FA
    Arch Intern Med; 1993 May; 153(9):1107-16. PubMed ID: 8481077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effective approach to the screening of HIV, HBV, HCV, HTLV in blood donors in France].
    Sailly JC; Lebrun T; Coudeville L
    Rev Epidemiol Sante Publique; 1997 Apr; 45(2):131-41. PubMed ID: 9221442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When does quality-adjusting life-years matter in cost-effectiveness analysis?
    Chapman RH; Berger M; Weinstein MC; Weeks JC; Goldie S; Neumann PJ
    Health Econ; 2004 May; 13(5):429-36. PubMed ID: 15127423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.